← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTLimited DatastalePreclinical
BCMA-UCART (BCMA-UCART)
Bioray Laboratories·BCMA
1 trials
Overview
Program
BCMA-UCART
Overview
Company
Bioray Laboratories
Overview
Modality
CGT
Overview
Target
BCMA
Overview
Indication
Multiple Myeloma
Overview
Phase
PRECLINICAL
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.. To investigate the efficacy of a nursing approach using B-cell maturation antigen (BCMA)-targeted universal chimeric antigen receptor T-cell (BCMA-UCART) immunotherapy in the treatment of 8 patients with relapsed refractory multiple myelom…
Toxicology
CRS
Reported
Clinical
Safety signal
Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.. To investigate the efficacy of a nursing approach using B-cell maturation antigen (BCMA)-targeted universal chimeric antigen receptor T-cell (BCMA-UCART) immunotherapy in the treatment of 8 patients with relapsed refractory multiple myelom…
Clinical
Program phase
PRECLINICAL